Lymphoma subtypes and tumor-associated features
| Pathologic diagnosis . | Vorinostat-EPOCH +/−R (n = 44), n (%) . | EPOCH +/−R (n = 42), n (%) . | All patients (N = 86), n (%) . | P* . |
|---|---|---|---|---|
| DLBCL | 30 (68) | 31 (73) | 61 (71) | |
| Subtype | .52 | |||
| GCB | 15/30 (50) | 19/31 (61) | 34/61 (56) | |
| Non-GCB | 14/30 (47) | 12/31 (39) | 26/61 (43) | |
| Unclassified DLBCL | 1/30 (3) | 0/31 (0) | 1/61 (2) | |
| EBV status | .23 | |||
| Positive | 9/30 (30) | 7/31 (22) | 16/61 (26) | |
| Negative | 13/30 (43) | 20/31 (65) | 33/61 (54) | |
| Inconclusive or ND | 8/30 (27) | 4/31 (13) | 12/61 (20) | |
| Bcl-2 protein expression | .07 | |||
| Positive | 15/30 (50) | 17/31 (55) | 32/61 (52) | |
| Negative | 7/30 (23) | 12/31 (39) | 19/61 (31) | |
| Inconclusive or ND | 8/30 (27) | 2/31 (6) | 10/61 (17) | |
| Myc protein expression | .05 | |||
| Positive | 8/30 (27) | 10/31 (32) | 18/61 (30) | |
| Negative | 11/30 (37) | 7/31 (23) | 18/61 (30) | |
| Inconclusive or ND | 11/30 (37) | 14/31 (45) | 25/61 (40) | |
| PBL | 8 (18) | 7 (17) | 15 (17) | |
| EBV status | .47 | |||
| Positive | 6/8 (75) | 7/7 (100) | 13/15 (87) | |
| Negative | 2/8 (25) | 0/7 (0) | 2/15 (13) | |
| Bcl-2 protein expression | .99 | |||
| Positive | 2/8 (25) | 3/7 (43) | 5/15 (33) | |
| Negative | 2/8 (25) | 1/7 (14) | 3/15 (20) | |
| Inconclusive or ND | 4/8 (50) | 3/7 (43) | 7/15 (47) | |
| Myc protein expression | .99 | |||
| Positive | 5/8 (63) | 4/7 (57) | 9/15 (60) | |
| Inconclusive or ND | 3/8 (37) | 3/7 (43) | 6/15 (40) | |
| PEL | 5 (11) | 2 (5) | 7 (8) | |
| EBV status | .99 | |||
| Positive | 3/5 (60) | 2/2 (100) | 5/7 (71) | |
| Negative | 2/5 (40) | 0/2 (0) | 2/7(29) | |
| Bcl-2 protein expression | .99 | |||
| Negative | 2/5 (40) | 1/2 (50) | 3/7 (43) | |
| Inconclusive or ND | 3/5 (60) | 1/2 (50) | 4/7 (57) | |
| Myc protein expression | .99 | |||
| Negative | 2/5 (40) | 1/2 (50) | 3/7 (43) | |
| Inconclusive or ND | 3/5 (60) | 1/2 (50) | 4/7 (57) | |
| BCL-U | 1 (2) | 1 (2) | 2 (2) | |
| EBV status | — | |||
| Negative | 1/1 (100) | 1/1 (100) | 2/2 (100) | |
| Bcl-2 protein expression | — | |||
| Positive | 1/1 (100) | 1/1 (100) | 2/2 (100) | |
| Myc protein expression | — | |||
| Positive | 1/1 (100) | 1/1 (100) | 2/2 (100) | |
| BL | 0 | 1 (2) | 1 (1) | |
| EBV status | — | |||
| Negative | 0/0 | 1/1 (100) | 1/1 (100) | |
| Bcl-2 protein expression | — | |||
| Negative | 0/0 | 1/1 (100) | 1/1 (100) | |
| Myc protein expression | — | |||
| Positive | 0/0 | 1/1 (100) | 1/1 (100) |
| Pathologic diagnosis . | Vorinostat-EPOCH +/−R (n = 44), n (%) . | EPOCH +/−R (n = 42), n (%) . | All patients (N = 86), n (%) . | P* . |
|---|---|---|---|---|
| DLBCL | 30 (68) | 31 (73) | 61 (71) | |
| Subtype | .52 | |||
| GCB | 15/30 (50) | 19/31 (61) | 34/61 (56) | |
| Non-GCB | 14/30 (47) | 12/31 (39) | 26/61 (43) | |
| Unclassified DLBCL | 1/30 (3) | 0/31 (0) | 1/61 (2) | |
| EBV status | .23 | |||
| Positive | 9/30 (30) | 7/31 (22) | 16/61 (26) | |
| Negative | 13/30 (43) | 20/31 (65) | 33/61 (54) | |
| Inconclusive or ND | 8/30 (27) | 4/31 (13) | 12/61 (20) | |
| Bcl-2 protein expression | .07 | |||
| Positive | 15/30 (50) | 17/31 (55) | 32/61 (52) | |
| Negative | 7/30 (23) | 12/31 (39) | 19/61 (31) | |
| Inconclusive or ND | 8/30 (27) | 2/31 (6) | 10/61 (17) | |
| Myc protein expression | .05 | |||
| Positive | 8/30 (27) | 10/31 (32) | 18/61 (30) | |
| Negative | 11/30 (37) | 7/31 (23) | 18/61 (30) | |
| Inconclusive or ND | 11/30 (37) | 14/31 (45) | 25/61 (40) | |
| PBL | 8 (18) | 7 (17) | 15 (17) | |
| EBV status | .47 | |||
| Positive | 6/8 (75) | 7/7 (100) | 13/15 (87) | |
| Negative | 2/8 (25) | 0/7 (0) | 2/15 (13) | |
| Bcl-2 protein expression | .99 | |||
| Positive | 2/8 (25) | 3/7 (43) | 5/15 (33) | |
| Negative | 2/8 (25) | 1/7 (14) | 3/15 (20) | |
| Inconclusive or ND | 4/8 (50) | 3/7 (43) | 7/15 (47) | |
| Myc protein expression | .99 | |||
| Positive | 5/8 (63) | 4/7 (57) | 9/15 (60) | |
| Inconclusive or ND | 3/8 (37) | 3/7 (43) | 6/15 (40) | |
| PEL | 5 (11) | 2 (5) | 7 (8) | |
| EBV status | .99 | |||
| Positive | 3/5 (60) | 2/2 (100) | 5/7 (71) | |
| Negative | 2/5 (40) | 0/2 (0) | 2/7(29) | |
| Bcl-2 protein expression | .99 | |||
| Negative | 2/5 (40) | 1/2 (50) | 3/7 (43) | |
| Inconclusive or ND | 3/5 (60) | 1/2 (50) | 4/7 (57) | |
| Myc protein expression | .99 | |||
| Negative | 2/5 (40) | 1/2 (50) | 3/7 (43) | |
| Inconclusive or ND | 3/5 (60) | 1/2 (50) | 4/7 (57) | |
| BCL-U | 1 (2) | 1 (2) | 2 (2) | |
| EBV status | — | |||
| Negative | 1/1 (100) | 1/1 (100) | 2/2 (100) | |
| Bcl-2 protein expression | — | |||
| Positive | 1/1 (100) | 1/1 (100) | 2/2 (100) | |
| Myc protein expression | — | |||
| Positive | 1/1 (100) | 1/1 (100) | 2/2 (100) | |
| BL | 0 | 1 (2) | 1 (1) | |
| EBV status | — | |||
| Negative | 0/0 | 1/1 (100) | 1/1 (100) | |
| Bcl-2 protein expression | — | |||
| Negative | 0/0 | 1/1 (100) | 1/1 (100) | |
| Myc protein expression | — | |||
| Positive | 0/0 | 1/1 (100) | 1/1 (100) |
BCL-U, B-cell lymphoma, unclassifiable, with features between DLBCL and BL; ND, not done.
P-values by 2-sided Fisher’s exact test.